ReviewBlood advances2019
The impact of response kinetics for multiple myeloma in the era of novel agents.
Review in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review.Frontiers in oncology · 2024Pooled it
- Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.Haematologica · 2024Trial
- A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.Nature genetics · 2026Article
- Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.Blood cancer journal · 2026Article
- Article
- Article
- Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.Annals of medicine · 2025Article
- Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma.Annals of hematology · 2025Article
- T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.Annals of hematology · 2024Article
- Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.Annals of hematology · 2024Article
- Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.Leukemia · 2024Article
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.Cancer medicine · 2024Article
- MiR-125b targeted regulation of MKNK2 inhibits multiple myeloma proliferation and invasion.American journal of translational research · 2024Article
- Longitudinal genetically detectable minimal residual disease by fluorescenceTherapeutic advances in medical oncology · 2024Article
- Article
- Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.Annals of hematology · 2023Article
- Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.Current hematologic malignancy reports · 2023Review
- Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.Cancer research communications · 2023Article
- Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma.Cell & bioscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 2 countries.
Funding
Abstract
Rapid remission by induction therapy has long been recognized as an important predictor for long-time survival in acute leukemia. However, the impact of response kinetics on multiple myeloma (MM) seems to be different and remains unexplored. The relationship between response kinetics and outcome were assessed in 626 patients with newly diagnosed MM who were included in a prospective, nonrandomized clinical trial (BDH 2008/02). Patients were assigned to either immunomodulatory drug- or proteasome inhibitor-based therapy. The response depth, time to best response (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.